KPIs & Operating Metrics(New)

Balance Sheet

Cash Flow Statement

Amortization of Goodwill Amortization of Goodwill Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Dividends Paid - Common Dividends Paid - Common Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Equity Investments Gains from Equity Investments Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt repayments

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Amortization - Goodwill Investment in Debt & Equity Leases Long-Term Debt Issuances Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Receivables - Other Revenue - Other Shares Issued Shares Outstanding Shares Outstanding Short-Term Debt repayments

Inovio Pharmaceuticals (INO) Long-Term Debt Repayments (2024)

Inovio Pharmaceuticals' Long-Term Debt Repayments history spans 1 years, with the latest figure at $16.4 million for Q1 2024.

On a quarterly basis, Long-Term Debt Repayments changed N/A to $16.4 million in Q1 2024 year-over-year; TTM through Dec 2024 was $16.4 million, a N/A change, with the full-year FY2024 number at $16.4 million, changed N/A from a year prior.
Long-Term Debt Repayments hit $16.4 million in Q1 2024 for Inovio Pharmaceuticals.
Over the last five years, Long-Term Debt Repayments for INO hit a ceiling of $16.4 million in Q1 2024 and a floor of $16.4 million in Q1 2024.